TY - JOUR
T1 - Somatostatin receptor scintigraphy
T2 - Its value in tumor localization in patients with cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion
AU - De Herder, Wouter W.
AU - Krenning, Eric P.
AU - Malchoff, Carl D.
AU - Hofland, Leo J.
AU - Reubi, Jean Claude
AU - Kwekkeboom, Dik J.
AU - Oei, H. Yoe
AU - Pols, Huibert A.P.
AU - Bruining, Hajo A.
AU - Nobels, Frank R.E.
AU - Lamberts, Steven W.J.
PY - 1994/4
Y1 - 1994/4
N2 - purpose: To assess the feasibility of somatostatin receptor scintigraphy for patients with Cushing's syndrome caused by tumors secreting ectopic corticotropin or corticotropin-releasing hormone (CRH). patients and methods: Ten patients with Cushing's syndrome, nine with ectopic corticotropin-secreting tumors and one with a CRH-secreting tumor, were consecutively studied. For comparison purposes, eight patients with corticotropin-secreting pituitary tumors and one patient with an autonomous adrenal adenoma were investigated. In vivo tumor localization was performed for all patients using a radionuclide-coupled somatostatin analog. The results obtained with this technique were compared with those obtained with conventional imaging techniques. For some patients, the clinical effects of octreotide therapy were evaluated. results: Somatostatin analog scintigraphy successfully identified the primary ectopic corticotropin-secreting and CRH-secreting tumors or their metastases, or both, in 8 of 10 patients; in 2 patients with corticotropin-secreting bronchial carcinoids, the tumors could not be visualized. Normal scans were obtained for the 8 patients with corticotropin-secreting pituitary tumors and the one patient with an adrenal adenoma. conclusion: Somatostatin analog scintigraphy can be included as a diagnostic step in the workup of Cushing's syndrome patients with a suspected ectopic corticotropin-secreting tumor or a CRH-secreting tumor.
AB - purpose: To assess the feasibility of somatostatin receptor scintigraphy for patients with Cushing's syndrome caused by tumors secreting ectopic corticotropin or corticotropin-releasing hormone (CRH). patients and methods: Ten patients with Cushing's syndrome, nine with ectopic corticotropin-secreting tumors and one with a CRH-secreting tumor, were consecutively studied. For comparison purposes, eight patients with corticotropin-secreting pituitary tumors and one patient with an autonomous adrenal adenoma were investigated. In vivo tumor localization was performed for all patients using a radionuclide-coupled somatostatin analog. The results obtained with this technique were compared with those obtained with conventional imaging techniques. For some patients, the clinical effects of octreotide therapy were evaluated. results: Somatostatin analog scintigraphy successfully identified the primary ectopic corticotropin-secreting and CRH-secreting tumors or their metastases, or both, in 8 of 10 patients; in 2 patients with corticotropin-secreting bronchial carcinoids, the tumors could not be visualized. Normal scans were obtained for the 8 patients with corticotropin-secreting pituitary tumors and the one patient with an adrenal adenoma. conclusion: Somatostatin analog scintigraphy can be included as a diagnostic step in the workup of Cushing's syndrome patients with a suspected ectopic corticotropin-secreting tumor or a CRH-secreting tumor.
UR - http://www.scopus.com/inward/record.url?scp=0028198129&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(94)90059-0
DO - 10.1016/0002-9343(94)90059-0
M3 - Article
C2 - 8166148
AN - SCOPUS:0028198129
SN - 0002-9343
VL - 96
SP - 305
EP - 312
JO - The American Journal of Medicine
JF - The American Journal of Medicine
IS - 4
ER -